Key facts
- It has raised $14.4M; the latest was Later Stage VC ($14.4M) in Feb 2026.
- Notable investors include South China Venture Capital, Biossom Investment Management, Hubei Renxi Science and Technology Innovation Industry Investment Private Equity Management, Share Capital, Zhongshan Jianzhuo Venture Capital Fund Partnership — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for FindCure
- ·The full record, as it builds
Funding rounds
No funding rounds for FindCure are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About FindCure
Developer of new anti-cancer drugs focused on targeting signaling pathways and immunotherapy. The company engages in the research and development of drugs targeting signaling pathways and immunotherapy, including small molecule targeted drugs, macromolecular proteins and antibody drugs with independent intellectual property rights, providing better drug solutions for cancer patients.
- Sector
- Healthcare
- HQ
- Zhongshan, China
- Founded
- 2019
- Employees
- 2
- Website
- findcure-bio.com/
- Ownership
- Privately Held (backing)
FindCure doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in FindCure shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on FindCure in its N-PORT filings yet. We sweep new filings monthly.